Back to results
US 2017/0304402 A1Published application
Use of low dose il-2 for treating autoimmune – related or inflammatory disorders
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Assistance Publique-Hopitaux de Paris, Universite Pierre Et Marie Curie (Paris 6)
InventorsDavid Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
Claims12
1-36. (canceled)
A method for treating systemic lupus erythematous, the method comprising:
- administering to the subject in need thereof interleukin-2 (IL-2) at a dose of no more than 3.5 MIU/day.
Dependencies are inferred from the claim text.